Literature DB >> 15838006

Continuation of trastuzumab beyond disease progression.

Filippo Montemurro, Roberto Faggiuolo, Stefania Redana, Michela Donadio, Monica Minischetti, Antonio Durando, Guido Vietti-Ramus, Roberta Buosi, Massimo Aglietta.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15838006     DOI： 10.1200/JCO.2005.05.177

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  4 in total

Review 1.  Trastuzumab: a review of its use in the management of HER2-positive metastatic and early-stage breast cancer.

Authors:  Greg L Plosker; Susan J Keam
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 2.  Cardiac toxicity with anti-HER-2 therapies: what have we learned so far?

Authors:  Evandro de Azambuja; Philippe L Bedard; Thomas Suter; Martine Piccart-Gebhart
Journal:  Target Oncol       Date:  2009-05-06       Impact factor: 4.493

3.  Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer.

Authors:  Alexandra Canonici; Merel Gijsen; Maeve Mullooly; Ruth Bennett; Noujoude Bouguern; Kasper Pedersen; Neil A O'Brien; Ioannis Roxanis; Ji-Liang Li; Esther Bridge; Richard Finn; Dennis Siamon; Patricia McGowan; Michael J Duffy; Norma O'Donovan; John Crown; Anthony Kong
Journal:  Oncotarget       Date:  2013-10

4.  Trastuzumab therapy duration in HER2-positive de novo metastatic breast cancer: 1999-2018.

Authors:  Henry G Kaplan; Judith A Malmgren; Boya Guo; Mary K Atwood
Journal:  Breast Cancer Res Treat       Date:  2022-07-22       Impact factor: 4.624
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.